Home/Pipeline/Datopotamab deruxtecan

Datopotamab deruxtecan

Non-small cell lung cancer (NSCLC)

Phase IIIActiveN/A

Key Facts

Indication

Non-small cell lung cancer (NSCLC)

Phase

Phase III

Status

Active

Company

AstraZeneca

About AstraZeneca

AstraZeneca is a global biopharmaceutical leader with a mission to push the boundaries of science to deliver life-changing medicines. The company has achieved significant commercial success with 16 blockbuster drugs and a robust pipeline of 197 projects, underpinned by a 'Growth Through Innovation' strategy focused on disease biology, next-generation therapeutics, predictive clinical success, and clinical innovation. AstraZeneca's strategic integration of data science, AI, and novel therapeutic modalities positions it to maintain its competitive edge and address complex healthcare challenges across its core therapeutic areas.

View full company profile

Therapeutic Areas

Oncology Cardiovascular/Renal/Metabolic Respiratory & Immunology Rare Disease Vaccines & Immune Therapies

Other Non-small cell lung cancer (NSCLC) Drugs

Drug	Company	Phase	Status
LW-02 Immunopheresis	Immunicom	Phase 2	Active
Idylla EGFR Mutation Assay	Biocartis	Approved	CE-IVD
ABD-3001	Advanced Biodesign	Phase 1	Active
Macrocyclic OMNI-EGFR Inhibitor	BlossomHill Therapeutics	Phase 1	Active
TUMORIN Clinical Trial	Nilogen Oncosystems	N/A (Diagnostic Validation)	Active
Membrex™	Metaclipse Therapeutics	Pre-clinical	Active
Lazertinib (Leclaza)	Genosco	Approved	Active
IPH5201 (anti-CD39 mAb)	Orega Biotech	Phase 2	Active
Platin-DRP®	Chosa Oncology	Validation	Active
Undisclosed RNA Immunotherapy	Epitopea	Pre-clinical	Active
Aspyre Clinical Test for Lung	Biofidelity	Commercial	Active
EGFR Mutation Detection Assay	Stilla Technologies	Assay Development/Validation	Active